Literature DB >> 25236160

A retrospective review and treatment paradigm of interventional therapies for patients suffering from intractable thoracic chest wall pain in the oncologic population.

Amitabh Gulati1, Rajiv Shah, Vinay Puttanniah, Joseph C Hung, Vivek Malhotra.   

Abstract

INTRODUCTION: Tumors invading the chest wall and pleura are often incurable, and treatment is targeted toward palliation of symptoms and control of pain. When patients develop tolerance or side effects to systemic opioid therapy, interventional techniques can better optimize a patient's pain. We performed a retrospective review of 146 patients from April 2004 to January 2014 who underwent diagnostic and therapeutic procedures for pain relief. Using four patients as a paradigm for neurolytic approaches to pain relief, we present a therapeutic algorithm for treating patients with intractable thoracic chest wall pain in the oncologic population.
MATERIAL AND METHODS: For each patient, we describe the use of intercostal/paravertebral nerve blocks and neurolysis, pulsed radiofrequency ablation (PRFA) of the thoracic nerve roots, or intrathecal pump placement to successfully treat the patient's chest wall pain. Analysis of 146 patient charts is also performed to assess effectiveness of therapy.
RESULTS: Seventy-nine percent of patients undergoing an intercostal nerve diagnostic blockade (with local anesthetic and steroid) stated that they had improved pain relief with 22% having prolonged pain relief (average of 21.5 days). Only 32% of successful diagnostic blockade patients elected to proceed to neurolysis, with a 62% success rate. Seven patients elected to proceed to intrathecal drug delivery. DISCUSSION: Intercostal nerve diagnostic blockade with local anesthetic and steroid may lead to prolonged pain relief in this population. Furthermore, depending on tumor location, we have developed a paradigm for the treatment of thoracic chest wall pain in the oncologic population. Wiley Periodicals, Inc.

Entities:  

Keywords:  Cancer Pain; Intercostal Nerve; Intercostal Neurolysis; Intrathecal Drug Delivery; Thoracic Chest Wall Pain

Mesh:

Substances:

Year:  2014        PMID: 25236160     DOI: 10.1111/pme.12558

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  6 in total

1.  Randomized controlled trials between dorsal root ganglion thermal radiofrequency, pulsed radiofrequency and steroids for the management of intractable metastatic back pain in thoracic vertebral body.

Authors:  Sherry Nabil Fanous; Emad Gerges Saleh; Ekramy Mansour Abd Elghafar; Hossam Zarif Ghobrial
Journal:  Br J Pain       Date:  2020-08-11

2.  An Interventional Pain Algorithm for the Treatment of Postmastectomy Pain Syndrome: A Single-Center Retrospective Review.

Authors:  Ajax Yang; Danielle Nadav; Aron Legler; Grant H Chen; Lee Hingula; Vinay Puttanniah; Amitabh Gulati
Journal:  Pain Med       Date:  2021-03-18       Impact factor: 3.750

Review 3.  Evidence-based Clinical Practice Guidelines for Interventional Pain Management in Cancer Pain.

Authors:  Sushma Bhatnagar; Maynak Gupta
Journal:  Indian J Palliat Care       Date:  2015 May-Aug

Review 4.  Interventional Analgesic Management of Lung Cancer Pain.

Authors:  Uri Hochberg; Maria Francisca Elgueta; Jordi Perez
Journal:  Front Oncol       Date:  2017-02-14       Impact factor: 6.244

5.  Modified technique for thermal radiofrequency ablation of Thoracic dorsal root ganglia under combined fluoroscopy and CT guidance: a randomized clinical trial.

Authors:  Raafat M Reyad; Hossam Z Ghobrial; Ehab H Shaker; Ehab M Reyad; Mohammed H Shaaban; Rania H Hashem; Wael M Darwish
Journal:  BMC Anesthesiol       Date:  2019-12-18       Impact factor: 2.217

6.  Microwave ablation with local pleural anesthesia for subpleural pulmonary nodules: our experience.

Authors:  Liangliang Meng; Bin Wu; Xiao Zhang; Xiaobo Zhang; Yingtian Wei; Xiaodong Xue; Zhongliang Zhang; Xin Zhang; Jing Li; Xiaofeng He; Li Ma; Yueyong Xiao
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.